Skip to content

To explore the cognitive impairment and intervention of transcutaneous vagus nerve stimulation in patients with primary headache using event-related potentials

To explore the cognitive impairment and intervention of transcutaneous vagus nerve stimulation in patients with primary headache using event-related potentials

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102050
Enrollment
Unknown
Registered
2025-05-07
Start date
2025-05-20
Completion date
Unknown
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Interventions

True stimulation group:Stimulation frequency of 25Hz, pulse width of 250Hz, intensity below individual pain threshold, treatment time of 20 minutes, once a day, total treatment period of 7 days
False stimulation group:Stimulation frequency of 25Hz, pulse width of 250Hz, 0.1mA, treatment time of 20 minutes, once a day, total treatment period of 7 days

Sponsors

Department of Neurology, the First Medical Center, Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) Diagnosed headache patients and healthy controls who meet (2) - (4) criteria according to the International Classification of Headaches, Third Edition (ICHD-3); (2) Right handedness; (3) Age range from 18 to 65 years old; (4) Failure to meet the standards for using preventive treatment or regular use of preventive treatment drugs within 3 months (5) Voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Neurological diseases (i.e. epilepsy, cerebral infarction, encephalitis, neuromuscular diseases); (2) Pregnant and lactating patients; (3) Intellectual disability; (4) Using prophylactic treatment for headaches within 3 months but irregularly; (5) Combined with other basic diseases, such as cardiovascular disease, diabetes, digestive system disease, respiratory system disease, etc; (6) Patients who take therapeutic drugs for other diseases for a long time.

Design outcomes

Primary

MeasureTime frame
P3;N2;

Secondary

MeasureTime frame
reaction time;accuracy;

Countries

China

Contacts

Public ContactZhao Dong

Department of Neurology, the First Medical Center, Chinese PLA GeneralHospital

xiesiyuan19981102@outlook.com+86 178 2201 1626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026